University of California and Partners Awarded Third U.S. CRISPR-Cas9 Patent
The U.S. Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent covering the use of one or multiple single guide RNAs in any cell type to the regents of the University of California (UC), the University of Vienna, and CRISPR pioneer Emmanuelle Charpentier, PhD, director and scientific member at the Max Planck Institute of Infection Biology, Berlin, UC said today.
U.S. Patent Number 10,227,611, “Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription,” covers the use of single molecule RNA guides and Cas9 protein in any cell, with the aim of creating efficient and effective ways for scientists to target and edit genes.
